The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.
Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.
The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.
GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer.
According to a new study, the company returns results for more than 90 percent of its GeneStrat tests within 72 hours and aims to bring that down to 48 hours.
The test, which the company plans to launch later this year, will use MALDI-based proteomics to assess patients' likelihood of responding to immunotherapies.
Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.
The deal gives the firm access to Bioyong's network of hospital-installed mass specs on which it hopes to place assays including its Veristrat lung cancer test.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
